Rabbit hemorrhagic disease virus VP60 protein expressed in recombinant swinepox virus self-assembles into virus-like particles with strong immunogenicity in rabbits

Changjin Liu, Lin Min, Huanyi Hu, Xiaolan Liu, Yan-Chao Bian, Xiaohua Huang, Xiaoxiang Li, Wenyang Yu, Feng Luo, Deng Shun-zhouFrontiers in Microbiology 2022 · DOI

TL;DR

Researchers have engineered a novel vaccine candidate for Rabbit Hemorrhagic Disease (RHD) using a modified swinepox virus (SWPV) to express the RHD virus (RHDV) VP60 protein. This recombinant virus successfully produced VP60 protein that self-assembled into virus-like particles (VLPs), demonstrating strong immunogenicity and providing complete protection against lethal RHDV challenge in rabbits.

What Problem Does This Paper Address?

Rabbit Hemorrhagic Disease (RHD) is a devastating and economically significant infectious disease affecting rabbits worldwide. A major hurdle in developing effective vaccines against RHDV is its difficulty in replicating in cell cultures in vitro. This limitation has historically hindered research into its replication mechanisms and the production of inactivated virus vaccines. While RHDV VP60 protein is a key antigen for subunit vaccines, traditional methods for its production are challenging. This paper aims to overcome these limitations by exploring a novel vaccine delivery system.

Methods

The researchers employed a recombinant swinepox virus (rSWPV) strategy. They constructed a modified SWPV where the thymidine kinase (TK) gene was deactivated to serve as an insertion site for the RHDV VP60 gene. Two versions were created: one expressing the VP60 protein and another expressing a VP60 protein with a His-tag for easier purification.

Key techniques included:

  • Recombinant Virus Construction: Using plasmid transfer vectors and homologous recombination to insert the VP60 gene into the SWPV genome.
  • Protein Expression Confirmation: Immunofluorescence Assay (IFA) and Western Blotting were used to verify the expression of the VP60 protein in infected cells.
  • Virus-Like Particle (VLP) Formation: Transmission Electron Microscopy (TEM) was utilized to visualize and confirm the self-assembly of the expressed VP60 protein into VLPs.
  • Immunogenicity and Efficacy Testing:
    • ELISA and Hemagglutination Inhibition (HI) Assays: To measure the levels of RHDV-specific antibodies induced in immunized rabbits.
  • Virus Challenge Studies: Rabbits were challenged with a lethal dose of RHDV to assess the protective efficacy of the vaccine candidates.
  • Histopathological and Immunohistochemical Analysis: To evaluate tissue damage and the distribution of RHDV antigen in challenged rabbits.

Datasets

Not discussed in the paper. The study primarily relies on in vitro cell culture experiments and in vivo animal models (rabbits).

Key Insights and Ideas

  • SWPV as a Viable Vaccine Vector: The study successfully demonstrates that swinepox virus can be effectively engineered to express foreign antigens like RHDV VP60, serving as a promising vaccine vector.
  • VP60 Self-Assembly into VLPs: The expressed VP60 protein, both with and without a His-tag, spontaneously self-assembles into virus-like particles (VLPs). This is significant because VLPs mimic the structure of natural viruses, enhancing immunogenicity without containing viral genetic material, thus improving safety.
  • Strong Humoral Immune Response: A single immunization with the rSWPV-VP60 candidates elicited high levels of neutralizing antibodies in rabbits, which were sustained for at least 13 weeks.
  • Complete Protection Against Lethal Challenge: The rSWPV-VP60 vaccines provided complete protection against a lethal RHDV challenge, with no observed mortality or significant histopathological damage in the vaccinated groups. This is a critical finding for a disease with high fatality rates.
  • Potential for Bivalent Vaccines: Given the high exogenous gene capacity of poxviruses and the emergence of RHDV type 2, the authors suggest this vector could be adapted for developing bivalent vaccines targeting multiple RHDV strains.

Key Results

  • Successful VP60 Expression: Recombinant SWPVs (rSWPV-VP60 and rSWPV-VP60-His) were successfully constructed and confirmed to express RHDV VP60 protein in PK15 cells.
  • VLP Formation: TEM confirmed that the expressed VP60 protein self-assembled into VLPs with diameters of 33-40 nm.
  • Robust Antibody Production: ELISA and HI assays showed that rabbits immunized with rSWPV-VP60 or rSWPV-VP60-His developed high titers of anti-VP60 antibodies, comparable to or exceeding those induced by a commercial RHDV vaccine.
  • 100% Survival Post-Challenge: All rabbits immunized with the rSWPV-VP60 candidates survived a lethal RHDV challenge, whereas the control group (immunized with inactivated SWPV) did not.
  • Reduced Pathological Impact: Histopathological analysis revealed significantly less tissue damage and RHDV antigen distribution in the lungs, liver, and spleen of rabbits vaccinated with rSWPV-VP60 compared to the control group.

Limitations and Future Work

  • Limited to RHDV Type 1: The study focused on the VP60 protein from classic RHDV. The emergence of RHDV type 2 necessitates further investigation into the efficacy of this vaccine against newer strains.
  • Need for Further Optimization: While promising, the authors suggest that further optimization of the rSWPV vector and expression system could potentially enhance immunogenicity and vaccine efficacy.
  • Future Work: The authors propose exploring the potential of this rSWPV vector for developing bivalent vaccines targeting both RHDV type 1 and type 2, leveraging the poxvirus's capacity for expressing multiple antigens. They also highlight the need for continued research into the long-term immunity and safety profiles of these recombinant vaccines.

Summary updated

Abstract

Rabbit Hemorrhagic Disease (RHD) is an economically significant infectious disease of rabbits, and its infection causes severe losses in the meat and fur industry. RHD Virus (RHDV) is difficult to proliferate in cell lines <i>in vitro</i>, which has greatly impeded the progress of investigating its replication mechanism and production of inactivated virus vaccines. RHDV VP60 protein is a major antigen for developing RHD subunit vaccines. Herein, we constructed a TK-deactivated recombinant Swinepox virus (rSWPV) expressing VP60 protein and VP60 protein coupled with His-tag respectively, and the expression of foreign proteins was confirmed using immunofluorescence assay and western blotting. Transmission electron microscopy showed that the recombinant VP60, with or without His-tag, self-assembled into virus-like particles (VLPs). Its efficacy was evaluated by comparison with available commercial vaccines in rabbits. ELISA and HI titer assays showed that high levels of neutralizing antibodies were induced at the first week after immunization with the recombinant strain and were maintained during the ongoing monitoring for the following 13 weeks. Challenge experiments showed that a single immunization with 10<sup>6</sup> PFU of the recombinant strain protected rabbits from lethal RHDV infection, and no histopathological changes or antigenic staining was found in the vaccine and rSWPV groups. These results suggest that rSWPV expressing RHDV VP60 could be an efficient candidate vaccine against RHDV in rabbits.
BibTeX
@inproceedings{liu2022rabbit,
  author = {Changjin Liu and Lin Min and Huanyi Hu and Xiaolan Liu and Yan-Chao Bian and Xiaohua Huang and Xiaoxiang Li and Wenyang Yu and Feng Luo and Deng Shun-zhou},
  title = {{Rabbit hemorrhagic disease virus VP60 protein expressed in recombinant swinepox virus self-assembles into virus-like particles with strong immunogenicity in rabbits}},
  booktitle = {Frontiers in Microbiology},
  year = {2022},
  doi = {10.3389/fmicb.2022.960374},
}
Figure